Which drug is classified as an NDRI and is used for treating depression with atypical features?

The classification of bupropion as a norepinephrine-dopamine reuptake inhibitor (NDRI) highlights its unique mechanism of action among antidepressants. Unlike selective serotonin reuptake inhibitors (SSRIs) like fluoxetine or sertraline, which primarily increase serotonin levels, bupropion specifically targets the reuptake of norepinephrine and dopamine. This can be particularly beneficial for individuals suffering from depression with atypical features, as it can help alleviate specific symptoms such as fatigue, low energy, and anhedonia.

Bupropion’s stimulant effects can also play a role in treating depressive symptoms that include lethargy and lack of motivation. Therefore, its use in treating depression with atypical features is well-supported by its pharmacological profile. This distinguishes it from the other options listed, each of which primarily operates on the serotonin system rather than having a balanced effect on norepinephrine and dopamine. Mirtazapine, while used for depression, works as an atypical antidepressant with different pathways and may not be as effective for atypical features specifically as bupropion.